肠源性内毒素血症在肝衰竭发生发展中的作用

高方媛; 王宪波

doi:10.3969/j.issn.1001-5256.2014.08.036

肠源性内毒素血症在肝衰竭发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2014.08.036

首都医科大学附属北京地坛医院

基金项目:

北京市科技计划课题(Z111107056811044)；北京市中医药科技发展基金科技提升专项(KJTS2011-05)；北京市卫生系统高层次人才专项(2013-2-11)；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 2630
- HTML全文浏览量: 31
- PDF下载量: 505
- 被引次数: 0
出版历程
- 收稿日期: 2013-11-04
- 出版日期: 2014-08-20

The role of intestinal endotoxemia in liver failure and its complications

Beijing Ditan Hospital Affiliated to Capital Medical University

Research funding:

摘要

摘要: 内毒素除了激活免疫反应,加重肝损伤和诱发肝衰竭之外,还可能与肝性脑病、肝肾综合征、自发性细菌性腹膜炎等多种致死性并发症的形成密切相关。归纳总结了肠源性内毒素血症(IETM)的形成机制及其在肝衰竭发生、发展过程中作用的最新研究进展,认为寻求预防和控制IETM的有效方法,是临床成功治疗严重肝病和肝衰竭的关键。
- 肝功能衰竭 /
- 内毒素血症 /
- 肝性脑病 /
- 腹膜炎 /
- 肝肾综合征 /
- 综述
Abstract: Recent studies have found that endotoxin not only activates immune response, exacerbates liver injury, and induces liver failure, but also plays an important role in the development of hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, and other fatal complications.The recent progress in research on the pathogenesis of intestinal endotoxemia (IETM) and its impact on the development and progression of liver failure is reviewed and summarized.It is suggested that seeking effective methods to prevent and control IETM holds promise as the key to treating severe liver disease and liver failure successfully.
- liver failure /
- endotoxemia /
- pathogenesis /
- hepatic encephalopathy /
- peritonitis /
- hepatorenal syndrome

HTML全文

参考文献(25)

[1]BAUER TM, SCHWACHA H, STEINBRCKNER B, et al.Small intestinal overgrowth and bacterial translocation in human cirrhosis is associated with systemic endotoxinemia[J].Am J Gastroenterol, 2002, 97 (9) :2364-2370.

[2] CHANG CS, CHEN GH, LIEN HC, et al.Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis[J].Hepatology, 1998, 28 (5) :1187-1190.

[3]BILZER M, ROGGEL F, GERBES AL.Role of Kupffer cells in host defense and liver disease[J].Liver Int, 2006, 26 (10) :1175-1186.

[4]SU GL.Lipopolysaccharides in liver injury:molecular mechanisms of Kupffer cell activation[J].Am J Physiol Gastrointest Liver Physiol, 2002, 283 (2) :g256-g265.

[5]VERBEKE L, NEVENS F, LALEMAN W.Bench-to-beside review:Acute-on-chronic liver failure-linking the gut, liver and systemic circulation[J].Critical Care, 2011, 15 (5) :233-243.

[6]ZHANG HY, HAN DW, WANG XG, et al.Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome[J].World J Gastroenterol, 2005, 11 (4) :567-572.

[7] SEKI E, BRENNER DA.Toll-like receptors and adaptor molecules in liver disease:update[J].Hepatology, 2008, 48 (1) :322-335.

[8]ANTONIADES CG, BERRY PA, WENDON JA, et al.The importance of immune dysfunction in determining outcome in acute liver failure[J].J Hepatol, 2008, 49 (5) :845-861.

[9]NOTAS G, KISSELEVA T, BRENNER D.NK and NKT cells in liver injury and fibrosis[J].Clin Immunol, 2009, 130 (1) :16-26.

[10]STEINHOFF G, BEHREND M, SCHRADER B, et al.Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia.Lack of ELAM-1 and CD62 inducibility on sinusoidal endothelia and distinct distribution of VCAM-1, ICAM-1, ICAM-2 and LFA-3[J].Am J Pathol, 1993, 142 (2) :481-488.

[11]ROCKEY DC, FOUASSIER L, CHUNG JJ, et al.Cellular localization of endothelin-1 and increased production in liver injury in the rat:potential for autocrine and paracrine effects on stellate cells[J].Hepatology, 1998, 27 (2) :472-480.

[12]HAN DW.Intestinal endotoxemia as a pathogenetic mechanism in liver failure[J].World J Gastroenterol, 2002, 8 (6) :961-965.

[13]LI JF, DUAN ZP.Acute-on-chronic liver failure:from pathophysiology to clinical practice[J].J Clin Hepatol, 2013, 29 (9) :641-644. (in Chinese) 李俊峰, 段钟平.慢加急性肝衰竭:从病理生理到临床实践[J].临床肝胆病杂志, 2013, 29 (9) :641-644.

[14]FERENCI P, LOCKWOOD A, MULLEN K, et al.Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification:final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998[J].Hepatology, 2002, 35 (3) :716-721.

[15]SHAWCROSS DL, WRIGHT G, OLDE DAMINK SW, et al.Role of ammonia and inflammation in minimal hepatic encephalopathy[J].Metab Brain Dis, 2007, 22 (1) :125-138.

[16]SHARIFI Y, YEOMAN A, AUSTIN M, et al.Defining the outcomes of severe hepatic encephalopathy in cirrhosis:inflammation is the key[J].Hepatology, 2008, 48 (Suppl) :1061A.

[17]LICINIO J, WONG ML.Pathways and mechanisms for cytokine signaling of the central nervous system[J].J Clin Invest, 1997, 100 (12) :2941-2947.

[18]SHAWCROSS DL, SHARIFI Y, CANAVAN JB, et al.Infection and systemic inflammation, not ammonia, are associated with Grade3/4 hepatic encephalopathy, but not mortality in cirrhosis[J].J Hepatol, 2011, 54 (4) :640-649.

[19]BELLOT P, FRANCSR, SUCH J.Pathological bacterial translocation in cirrhosis:pathophysiology, diagnosis and clinical implications[J].Liver Int, 2013, 33 (1) :31-39.

[20]MOORE K.The hepatorenal syndrome[J].Clin Sci (Lond) , 1997, 92 (5) :433-443.

[21]MAZUR JE, COOPER TB, DASTA JF.Terlipressin in hepatorenal syndrome[J].Ann Pharmacoter, 2011, 45 (3) :380-387.

[22]KAYALI Z, HERRING J, BARON P, et al.Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction[J].J Gastroenterol Hepatol, 2009, 24 (6) :1030-1037.

[23] WEERATEERANGKUL P, CHATTIPAKORN S, CHATTIPAKORN N.Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia-reperfusion injury[J].Med Sci Monit, 2011, 17 (2) :RA44-52.

[24]GARCIA-TSAO G.Bacterial translocation:cause or consequence of decompensation in cirrhosis?[J].J Hepatol, 2001, 34 (1) :150-155.

[25]DIAL EJ, TRAN DM, HYMAN A, et al.Endotoxin-induced changes in phospholipid dynamics of the stomach[J].J Surg Res, 2013, 180 (1) :140-146.

施引文献

资源附件(0)

访问统计